Cocrystal Pharma, Inc. - Common Stock, par value $0.001 per share (COCP)
CUSIP: 19188J409
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 13,831,528
- Total 13F shares
- 674,355
- Share change
- -46,967
- Total reported value
- $1,571,278
- Price per share
- $2.33
- Number of holders
- 13
- Value change
- -$90,505
- Number of buys
- 5
- Number of sells
- 7
Quarterly Holders Quick Answers
What is CUSIP 19188J409?
CUSIP 19188J409 identifies COCP - Cocrystal Pharma, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 19188J409:
Top shareholders of COCP - Cocrystal Pharma, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
2%
|
275,656
|
$385,918 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.91%
|
126,028
|
$176,000 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.53%
|
73,746
|
$103,244 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.44%
|
60,432
|
$86,436 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.43%
|
59,271
|
$82,979 | — | 31 Mar 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.38%
|
52,130
|
$74,546 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.18%
|
24,443
|
$34,953 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.15%
|
20,258
|
$28,361 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.09%
|
12,207
|
$17,090 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.06%
|
8,975
|
$12,565 | — | 31 Mar 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.05%
|
7,456
|
$10,439 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
543
|
$776 | — | 31 Mar 2024 | |
| VIMA LLC |
13F
|
Company |
0%
|
231
|
$461 | — | 31 Mar 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
93
|
$130 | — | 31 Mar 2024 | |
| NVWM, LLC |
13F
|
Company |
0%
|
84
|
$118 | — | 31 Mar 2024 |
Institutional Holders of Cocrystal Pharma, Inc. - Common Stock, par value $0.001 per share (COCP) as of Q2 2024
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.